Tumor-intrinsic IFNα and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03761-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Chun-Chia Cheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Radiation Medicine, Chang Gung University, Taoyuan, 333, Taiwan. Hauptthemen laut MEDLINE: Chemokine CXCL10, Tumor Microenvironment, Interferon-alpha, Immunotherapy. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council.
Abstract (Originalsprache)
Tumor immunotherapies targeting PD-(L)1 exhibit anti-tumor efficacy in only 10–30% of patients with various cancers. Literature has demonstrated that a “hot tumor” which contains high T lymphocytes in the tumor microenvironment exhibits a better response to immunotherapies than a “cold tumor.” This study aimed to investigate whether tumor-intrinsic IFNα and CXCL10 determine the recruitment and activation of CD8 + T cells to become “hot tumor.” In this study, we found that CXCL10 overexpressed in a variety of tumors including lung, colon, and liver tumors with a correlation with PD-L1. High PD-L1 and CXCL10 are associated with better survival rates in tumor patients receiving immunotherapies. IFNs-downstream transcriptional factor IRF-1 and STAT1 were correlated with PD-L1 and CXCL10 expression. We demonstrated that IRF-1 and STAT1 were both bound with the promoters of PD-L1 and CXCL10, sharing the same signaling pathway and determining IFNs-mediated PD-L1 and CXCL10 expression. In addition, IFNα significantly increased activation marker IFNγ in PBMCs, promoting M1 type monocyte differentiation, CD4 + T, and CD8 + T cell activation. Particularly, we found that CD8 + T lymphocytes abundantly expressed CXCR3, a receptor of CXCL10, by flow cytometry, indicating that tumor-intrinsic CXCL10 potentially recruited CD8 + T in tumor microenvironment. To demonstrate the hypothesis, immunotherapy-sensitive CT26 and immunotherapy-resistant LL/2 were used and we found that CT26 cells exhibited higher IFNα, IFNγ, CXCL10, and PD-L1 levels compared to LL/2, leading to higher IFNγ expression in mouse splenocytes. Moreover, we found that CD8 + T cells were recruited by CXCL10 in vitro, whereas SCH546738, an inhibitor of CXCR3, inhibited T cell migration and splenocytes-mediated anti-tumor effect. We then confirmed that CT26-derived tumor was sensitive to αPD-L1 immunotherapy and LL/2-tumor was resistant, whereas αPD-L1 significantly increased T lymphocyte activation marker CD107a in CT26-derived BALB/c mice. In conclusion, this study revealed that CXCL10 expression is correlated with PD-L1 in tumors, sharing the same signaling pathway and associating with better immunotherapeutic efficacy. Further evidence in the syngeneic tumor models demonstrated that immunotherapy-sensitive CT26 intrinsically exhibited higher IFNα and CXCL10 compared to immunotherapy-resistant LL/2 to recruit and activate CD8 + T cells in the tumor microenvironment, exhibiting “hot tumor” characteristic of sensitizing αPD-L1 immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center of Radiation Medicine, Chang Gung University, Taoyuan, 333, Taiwan.
- Division of Pulmonary Oncology and Interventional Bronchoscopy, Department of Thoracic Medicine, Chang Gung Memorial Hospital, Linkou, Taoyuan, 333, Taiwan.
- Graduate Institute of Medical Sciences, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan.
- Division of Gastroenterology, Cheng Hsin General Hospital, Taipei, 112, Taiwan.
- Department of Isotope Application Research, National Atomic Research Institute, Taoyuan, 325, Taiwan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, 110, Taiwan. chunchao@tmu.edu.tw.
Förderung
- National Science and Technology Council
Zitieren
APA
Cheng, C. C., Chang, J., Ho, A. S., Sie, Z. L., Peng, C. L., Wang, C. L., Dev, K., & Chang, C. C. (2024). Tumor-intrinsic IFNα and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03761-y
Vancouver
Cheng CC, Chang J, Ho AS, Sie ZL, Peng CL, Wang CL, et al. Tumor-intrinsic IFNα and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03761-y
BibTeX
@article{Cheng2024,
author = {Cheng, Chun-Chia and Chang, Jungshan and Ho, Ai-Sheng and Sie, Zong-Lin and Peng, Cheng-Liang and Wang, Chih-Liang and Dev, Kapil and Chang, Chun-Chao},
title = {Tumor-intrinsic IFNα and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03761-y}
}
EUVIMED